Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily)Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients Infected With HIV-1

Next Previous
Trial Profile

A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily)Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients Infected With HIV-1

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Stavudine (Primary) ; Efavirenz; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Feb 2019 Results assessing Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine published in the JAIDS
  • 31 Oct 2018 Primary endpoint has been met. (Number of participants with undetectable plasma HIV-1 RNA levels)
  • 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top